Monday, Jan 27, 2003

Genentech Appoints Ian Clark Senior Vice President and General Manager, BioOncology

South San Francisco, Calif. -- January 27, 2003 --

Genentech (NYSE: DNA) today announced the appointment of Ian Clark to senior vice president and general manager, BioOncology. Clark reports to Myrtle Potter, executive vice president, Commercial Operations, and chief operating officer.

In his new role, Clark is responsible for leading the company's commercial efforts in BioOncology, including overseeing sales, marketing and planning for the hematology and oncology franchises. In addition, Clark serves on Genentech's Product Portfolio Committee, charged with providing strategic and financial oversight of the company's drug development portfolio.

"Ian's extensive experience and outstanding strategic insights will be great assets as we look forward to building our presence in oncology and hematology by ensuring continued strong performance of our existing products and preparing for the possibility of new products," said Potter.

Clark, 42, joins Genentech from Novartis, where he served as president of Novartis Canada. Before assuming his post in Canada, Clark served as chief operating officer for Novartis United Kingdom. Prior to joining Novartis in 1999, Clark worked in positions of increasing strategic importance in sales, marketing and business development at Ivax Pharma and Sanofi-Synthelabo in the United Kingdom. Clark started his career at Pharmacia, holding positions in both sales and marketing.

Clark received a Bachelor of Science degree in biological sciences from Southampton University in the United Kingdom.

Genentech is a leading biotechnology company that discovers, develops, manufactures, and commercializes biotherapeutics for significant unmet medical needs. Fifteen of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes ten biotechnology products directly in the United States. The company has headquarters in South San Francisco, California, and is traded on the New York Stock Exchange under the symbol DNA.

 

# # #